Plasma β-III tubulin, neurofilament light chain and glial fibrillary acidic protein are associated with neurodegeneration and progression in schizophrenia.
Daniela Rodrígues-AmorímTania Rivera-BaltanásMaría Del Carmen Vallejo-CurtoCynthia Rodriguez-JamardoElena de Las HerasCarolina Barreiro-VillarMaría Blanco-FormosoPatricia Fernández-PalleiroMaría Álvarez-ArizaMarta LópezAlejandro García-CaballeroJosé Manuel OlivaresCarlos SpuchPublished in: Scientific reports (2020)
Schizophrenia is a progressive disorder characterized by multiple psychotic relapses. After every relapse, patients may not fully recover, and this may lead to a progressive loss of functionality. Pharmacological treatment represents a key factor to minimize the biological, psychological and psychosocial impact of the disorder. The number of relapses and the duration of psychotic episodes induce a potential neuronal damage and subsequently, neurodegenerative processes. Thus, a comparative study was performed, including forty healthy controls and forty-two SZ patients divided into first-episode psychosis (FEP) and chronic SZ (CSZ) subgroups, where the CSZ sub group was subdivided by antipsychotic treatment. In order to measure the potential neuronal damage, plasma levels of β-III tubulin, neurofilament light chain (Nf-L), and glial fibrillary acidic protein (GFAP) were performed. The results revealed that the levels of these proteins were increased in the SZ group compared to the control group (P < 0.05). Moreover, multiple comparison analysis showed highly significant levels of β-III tubulin (P = 0.0002), Nf-L (P = 0.0403) and GFAP (P < 0.015) in the subgroup of CSZ clozapine-treated. In conclusion, β-III tubulin, Nf-L and GFAP proteins may be potential biomarkers of neurodegeneration and progression in SZ.
Keyphrases
- bipolar disorder
- end stage renal disease
- newly diagnosed
- ejection fraction
- oxidative stress
- chronic kidney disease
- lps induced
- multiple sclerosis
- prognostic factors
- randomized controlled trial
- spinal cord
- clinical trial
- patient reported outcomes
- risk assessment
- pi k akt
- immune response
- mental health
- cerebrospinal fluid
- small molecule
- spinal cord injury
- single cell
- toll like receptor
- human health
- blood brain barrier
- subarachnoid hemorrhage
- double blind